Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, ...

CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) ...

"Our third consecutive record quarter highlights NeoVolta’s ability to scale production and capture market share,” said Ardes Johnson, CEO of NeoVolta. "In a market where annual growth is typically ...